TransMedics Group, Inc. (TMDX) Stock Analysis
Falling Knife setup
Healthcare · Medical Devices
Sell if holding. Momentum 2.9/10 is below the 5.0 floor at $66.15 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.7): -1.0; Weak growth.
TransMedics develops the Organ Care System (OCS), the only FDA-approved portable multi-organ warm perfusion platform for heart, lung, and liver transplants, and provides the National OCS Program (NOP) as a turnkey outsourced procurement and logistics service. Revenue of $605.5M... Read more
Sell if holding. Momentum 2.9/10 is below the 5.0 floor at $66.15 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.7): -1.0; Weak growth. Chart setup: Death cross, below all MAs, RSI 18, MACD bearish. Score 5.4/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 72d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — TransMedics Group, Inc.
Latest news
- TransMedics (TMDX) Enters Agreement to Invest in PAD Aviation fo - GuruFocus — GuruFocus positive
- M&T Bank Corp Grows Stock Holdings in TransMedics Group, Inc. $TMDX - MarketBeat — MarketBeat neutral
- TransMedics Group Inc (TMDX) Shares Fall 6.3% -- What GF Score o - GuruFocus — GuruFocus negative
- TransMedics Group (TMDX) to Release Quarterly Earnings on Tuesday - MarketBeat — MarketBeat neutral
- Why TransMedics (TMDX) Is Up 8.2% After Record OCS Volumes And First Full Year Cash Flow - simplywall.st — simplywall.st positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 2.9/10 is below the 5.0 floor at $66.15 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Leverage penalty (D/E 1.7): -1.0; Weak growth. Chart setup: Death cross, below all MAs, RSI 18, MACD bearish. Prior stop was $61.49. Score 5.4/10, moderate confidence.
Take-profit target: $102.56 (+55.1% upside). Prior stop was $61.49. Stop-loss: $61.49.
Leverage penalty (D/E 1.7): -1.0; Weak growth; Negative momentum.
TransMedics Group, Inc. trades at a P/E of 15.6 (forward 19.2). TrendMatrix value score: 6.8/10. Verdict: Sell.
20 analysts cover TMDX with a consensus score of 4.2/5. Average price target: $118.
What does TransMedics Group, Inc. do?TransMedics develops the Organ Care System (OCS), the only FDA-approved portable multi-organ warm perfusion platform...
TransMedics develops the Organ Care System (OCS), the only FDA-approved portable multi-organ warm perfusion platform for heart, lung, and liver transplants, and provides the National OCS Program (NOP) as a turnkey outsourced procurement and logistics service. Revenue of $605.5M in 2025 (37% growth) is largely recurring from single-use OCS disposable sets.